656 related articles for article (PubMed ID: 32696234)
1. Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies.
Ragia G; Manolopoulos VG
Eur J Clin Pharmacol; 2020 Dec; 76(12):1623-1630. PubMed ID: 32696234
[TBL] [Abstract][Full Text] [Related]
2. The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
Yamamoto M; Kiso M; Sakai-Tagawa Y; Iwatsuki-Horimoto K; Imai M; Takeda M; Kinoshita N; Ohmagari N; Gohda J; Semba K; Matsuda Z; Kawaguchi Y; Kawaoka Y; Inoue JI
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532094
[TBL] [Abstract][Full Text] [Related]
3. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Hoffmann M; Kleine-Weber H; Schroeder S; Krüger N; Herrler T; Erichsen S; Schiergens TS; Herrler G; Wu NH; Nitsche A; Müller MA; Drosten C; Pöhlmann S
Cell; 2020 Apr; 181(2):271-280.e8. PubMed ID: 32142651
[TBL] [Abstract][Full Text] [Related]
5. ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?
Xiao L; Sakagami H; Miwa N
Viruses; 2020 Apr; 12(5):. PubMed ID: 32354022
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Cadegiani FA; Goren A; Wambier CG
Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
[TBL] [Abstract][Full Text] [Related]
7. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19.
Dong M; Zhang J; Ma X; Tan J; Chen L; Liu S; Xin Y; Zhuang L
Biomed Pharmacother; 2020 Nov; 131():110678. PubMed ID: 32861070
[TBL] [Abstract][Full Text] [Related]
8. ACE2/ADAM17/TMPRSS2 Interplay May Be the Main Risk Factor for COVID-19.
Zipeto D; Palmeira JDF; Argañaraz GA; Argañaraz ER
Front Immunol; 2020; 11():576745. PubMed ID: 33117379
[TBL] [Abstract][Full Text] [Related]
9. H
Yang G
Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982
[TBL] [Abstract][Full Text] [Related]
10. Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.
Choudhary S; Silakari O
Virus Res; 2020 Nov; 289():198146. PubMed ID: 32866534
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 and renin-angiotensin system inhibition: role of angiotensin converting enzyme 2 (ACE2) - Is there any scientific evidence for controversy?
Aleksova A; Ferro F; Gagno G; Cappelletto C; Santon D; Rossi M; Ippolito G; Zumla A; Beltrami AP; Sinagra G
J Intern Med; 2020 Oct; 288(4):410-421. PubMed ID: 32459372
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 and androgen-targeted therapy for prostate cancer patients.
Bhowmick NA; Oft J; Dorff T; Pal S; Agarwal N; Figlin RA; Posadas EM; Freedland SJ; Gong J
Endocr Relat Cancer; 2020 Sep; 27(9):R281-R292. PubMed ID: 32508311
[TBL] [Abstract][Full Text] [Related]
14. Candidate drugs against SARS-CoV-2 and COVID-19.
McKee DL; Sternberg A; Stange U; Laufer S; Naujokat C
Pharmacol Res; 2020 Jul; 157():104859. PubMed ID: 32360480
[TBL] [Abstract][Full Text] [Related]
15. Expression of SARS-CoV-2 receptor ACE2 and TMPRSS2 in human primary conjunctival and pterygium cell lines and in mouse cornea.
Ma D; Chen CB; Jhanji V; Xu C; Yuan XL; Liang JJ; Huang Y; Cen LP; Ng TK
Eye (Lond); 2020 Jul; 34(7):1212-1219. PubMed ID: 32382146
[TBL] [Abstract][Full Text] [Related]
16. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis.
Hou Y; Zhao J; Martin W; Kallianpur A; Chung MK; Jehi L; Sharifi N; Erzurum S; Eng C; Cheng F
BMC Med; 2020 Jul; 18(1):216. PubMed ID: 32664879
[TBL] [Abstract][Full Text] [Related]
17. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures.
Dinnon KH; Leist SR; Schäfer A; Edwards CE; Martinez DR; Montgomery SA; West A; Yount BL; Hou YJ; Adams LE; Gully KL; Brown AJ; Huang E; Bryant MD; Choong IC; Glenn JS; Gralinski LE; Sheahan TP; Baric RS
Nature; 2020 Oct; 586(7830):560-566. PubMed ID: 32854108
[TBL] [Abstract][Full Text] [Related]
18.
Bao R; Hernandez K; Huang L; Luke JJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32675312
[TBL] [Abstract][Full Text] [Related]
19. Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators.
Gkogkou E; Barnasas G; Vougas K; Trougakos IP
Redox Biol; 2020 Sep; 36():101615. PubMed ID: 32863223
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors.
Milne S; Yang CX; Timens W; Bossé Y; Sin DD
Lancet Respir Med; 2020 Jun; 8(6):e50-e51. PubMed ID: 32411576
[No Abstract] [Full Text] [Related]
[Next] [New Search]
